Ip MS, et al. - Researchers performed this secondary analysis of a nonrandomized trial in which 49 patients with central retinal or hemiretinal vein occlusion responded poorly to treatment with bevacizumab or aflibercept, to examine how switching treatment influences visual acuity or central subfield thickness in these patients. Outcomes suggest improvement in visual acuity and central subfield thickness at month 12 in eyes with treatment switched from bevacizumab to aflibercept at month 6. This suggests a possible achievement of benefit from switching to aflibercept treatment in eyes with central retinal or hemiretinal vein occlusion that have a poor response to bevacizumab. In few eyes, due to a poor response to aflibercept, treatment was switched to dexamethasone. In this study, due to the small sample size and lack of controls, researchers could not make definitive conclusions.